Hubbry Logo
Seborrhoeic dermatitisSeborrhoeic dermatitisMain
Open search
Seborrhoeic dermatitis
Community hub
Seborrhoeic dermatitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Seborrhoeic dermatitis
Seborrhoeic dermatitis
Seborrhoeic dermatitis
View on Wikipedia
from Wikipedia

Seborrhoeic dermatitis
Other namesSebopsoriasis, seborrhoeic eczema, pityriasis capitis[1]
Seborrhoeic dermatitis of the face
SpecialtyDermatology
SymptomsFlaking, dry or greasy, red, itchy, and inflamed skin[2][3]
DurationSeveral weeks to lifelong[4]
CausesMultiple factors[4]
Risk factorsStress, dry skin or excessive sebum, winter, poor immune function, Parkinson disease[4], genetics
Diagnostic methodBased on symptoms[4]
Differential diagnosisPsoriasis, atopic dermatitis, tinea capitis, rosacea, systemic lupus erythematosus[4]
TreatmentHumidifier
MedicationAntifungal cream, anti-inflammatory agents, coal tar, phototherapy[3]
Frequency~5% (adults),[4] ~10% (babies)[5]
Cradle cap, which is seborrhoeic dermatitis of the infant scalp

Seborrhoeic dermatitis (also spelled seborrheic dermatitis in American English) is a long-term skin disorder.[4] Symptoms include flaky, scaly, greasy, and occasionally itchy and inflamed skin.[2][3] Areas of the skin rich in oil-producing glands are often affected including the scalp, face, and chest.[4] It can result in social or self-esteem problems.[4] In babies, when the scalp is primarily involved, it is called cradle cap.[2] Mild seborrhoeic dermatitis of the scalp may be described in lay terms as dandruff due to the dry, flaky character of the skin.[6] However, as dandruff may refer to any dryness or scaling of the scalp, not all dandruff is seborrhoeic dermatitis.[6] Seborrhoeic dermatitis is sometimes inaccurately referred to as seborrhoea.[4]

The cause is unclear but believed to involve a number of genetic and environmental factors.[2][4] Risk factors for seborrhoeic dermatitis include poor immune function, Parkinson's disease, and alcoholic pancreatitis.[4][6] The condition may worsen with stress or during the winter.[4] Malassezia yeast is believed to play a role.[6] It is not a result of poor hygiene.[7] Diagnosis is typically clinical and based on the symptoms present.[4][8] The condition is not contagious.[9]

The typical treatment is topical antifungal cream and anti-inflammatory agents.[3] Specifically, ketoconazole or ciclopirox are effective.[10] Seborrhoeic dermatitis of the scalp is often treated with shampoo preparations of ketoconazole, zinc pyrithione, and selenium.[11]

The condition is common in infants within the first three months of age or adults aged 30 to 70 years.[2][4][5] It tends to affect more males.[12] Seborrhoeic dermatitis is more common in African Americans, among immune-compromised individuals, such as those with HIV, and individuals with Parkinson's disease.[11][12]

Signs and symptoms

[edit]
Seborrhoeic dermatitis on upper face/head
Seborrhoeic dermatitis on the shoulder
Seborrhoeic dermatitis on eyelids
Seborrhoeic dermatitis on the eyebrows and scalp

Seborrhoeic dermatitis typically appears as oily, yellowish, flaky skin. Although commonly associated with oily skin, it can also appear on dry scalps or skin, where the flaking may look similar to dandruff. The flakes can be fine, loose, and diffuse or thick and adherent.[11][8] In addition to flaky skin, seborrhoeic dermatitis can have areas of red, rashy, inflamed, and itchy skin that coincide with the area of skin flaking, but not all individuals have this symptom.[8]

Seborrhoeic dermatitis of the scalp can appear similarly to dandruff.[11] When the scalp is affected, there can be associated temporary hair loss.[11] Such hair loss varies in appearance from diffuse thinning to patchy areas of hair loss.[11] On close inspection, the locations where hair has thinned may have broken stubs of hair and pustules around the hair follicles.[11] Individuals with more pigmented skin tones may experience increased or decreased skin pigmentation in affected areas.[12]

Various locations can be affected by seborrhoeic dermatitis. Commonly affected areas include the face, ears, scalp, and across the body. It is less common in intertriginous areas, which are areas where the skin folds and comes into contact with itself, such as the groin or the underarms.[11]

Seborrhoeic dermatitis' symptoms are typically mild and appear gradually but are often persistent, lasting weeks to years.[8][11][13] Individuals with seborrhoeic dermatitis are subject to recurrent bouts and it may be a lifelong condition.[8] Seborrhoeic dermatitis can also occur quickly and severely in patients with Human Immunodeficiency Virus (HIV). This is sometimes the first indication of HIV.[12]

Causes

[edit]

The cause of seborrhoeic dermatitis has not been fully clarified as of 2019.[14][15]

In addition to the presence of Malassezia, genetic, environmental, hormonal, and immune-system factors are necessary for and/or modulate the expression of seborrhoeic dermatitis.[16][17] The condition may be aggravated by illness, psychological stress, fatigue, sleep deprivation, change of season, and reduced general health.[18]

Fungi

[edit]

The condition is thought to be due to a local inflammatory response to overgrowth by Malassezia fungi species in sebum-producing skin areas including the scalp, face, chest, back, underarms, and groin.[3][15] This is based on observations of high counts of Malassezia species in skin affected by seborrhoeic dermatitis and on the effectiveness of antifungals in treating the condition.[15] Species of Malassezia implicated in Seborrhoeic dermatitis include M. furfur (formerly Pityrosporum ovale), M. globosa, M. restricta, M. sympodialis, and M. slooffiae.[3]

Malassezia appears to be a significant factor in seborrhoeic dermatitis, but it is thought that other factors are necessary for the presence of Malassezia to result in seborrhoeic dermatitis.[15] For example, summer growth of Malassezia in the skin alone does not result in seborrhoeic dermatitis.[15] Besides antifungals, the effectiveness of anti-inflammatory drugs, which reduce inflammation, and antiandrogens, which reduce sebum production, provide further insights into the pathophysiology of seborrhoeic dermatitis.[3][19][20]

Bacteria

[edit]

Several bacteria, including Propionibacterium species and Staphylococcus aureus, have been shown to have some level of interaction with seborrhoeic dermatitis, though their exact impact is not known.[21][12]

Nutrition

[edit]

Seborrhoeic dermatitis-like eruptions are also associated with pyridoxine (vitamin B6) and riboflavin (vitamin B2) deficiency.[22][8] In children and babies, issues with Δ6-desaturase enzymes[18] have been correlated with increased risk.

Immune dysfunction

[edit]

Those with immunodeficiency (especially infection with HIV) and with neurological disorders that may impact immune system function such as Parkinson's disease (for which the condition is an autonomic sign) and stroke are particularly prone to it.[23][unreliable medical source?]

Climate

[edit]

Climate can affect seborrheic dermatitis, but there is a lack of consensus about which climates tend to exacerbate seborrheic dermatitis the most. Some studies show low humidity and low temperature are responsible for the high frequency of seborrheic dermatitis.[24] Others suggest hot environments may also worsen seborrhoeic dermatitis.[12] Yet another described that high humidity and low UV exposure are culpable.[25] Dry skin and an impaired skin barrier contribute to the condition.[12][21] It is likely that climate and weather variations affect the water and lipid content of skin.[21]

Mechanism

[edit]

Seborrhoeic dermatitis is a complex condition with many interacting factors that are not yet fully explained.[15] In general, the major factors that influence the development and severity include Malassezia yeast present on and in the skin, skin production of oily sebum, and a subsequent inflammatory response against Malassezia and their byproducts.[12] Additional factors involved in the condition are a compromised skin barrier, the makeup and amount of sebum produced, the character of the immune response and inflammation, and the presence of other microbe species inhabiting the skin.[15][12]

A suggested series of events leading to seborrhoeic dermatitis is an initially damaged skin barrier and abnormal sebum production, which leads to a change in the microbiome of the skin that in turn elicits an immune response.[15] An alternative explanation is an increase in sebum production feeding an increase in the Malassezia population that instigates inflammation; the inflammation then causes cellular changes that damage the skin barrier. This barrier disruption then encourages additional Malassezia growth and inflammation and again worsens skin barrier function.[12]

Diagnosis

[edit]

Typically, seborrhoeic dermatitis is a clinical diagnosis based on a physician's expertise in identifying and differentiating skin conditions based on the history of the individual and the appearance of the skin.[8] However, seborrhoeic dermatitis may also be diagnosed with additional testing. The least invasive test is a visual inspection in the clinic using a Wood's Lamp.[11] A KOH test can also be used, where skin scraping of the affected skin may also be taken and prepared with potassium hydroxide (KOH) and visualized under a microscope to look for Malassezia or other microbiological cells. Additionally, a fungal culture of the affected skin may be taken to attempt to grow and identify the causative organism.[11]

Differential diagnosis

[edit]

Seborrhoeic dermatitis can look similar to other skin conditions that share its characteristic dry, flaky, scaly, and inflamed appearance, but have different causes and treatments. Physicians use the history of the individual with the skin condition as well as other tests to identify which disorder is present. Other conditions that may be confused with seborrhoeic dermatitis based on appearance are listed below.[8][11]

Management

[edit]

Medications

[edit]

A variety of different types of medications can reduce symptoms of seborrhoeic dermatitis.[3] These include certain antifungals, anti-inflammatory agents like corticosteroids and nonsteroidal anti-inflammatory drugs, antiandrogens, and antihistamines, among others.[3][14] Treatments must take into consideration potential side effects, especially with long-term use given the chronic nature of seborrhoeic dermatitis.[neutrality is disputed] Initial therapy is usually a topical preparation with an agreeable side effect profile.[12]

Antifungals

[edit]

Regular use of an over-the-counter or prescription antifungal shampoo or cream is a common treatment. The topical antifungal medications ketoconazole and ciclopirox have the best evidence.[10] Ketoconazole should be used twice per week.[8] Shampoo or soap containing zinc pyrithione or selenium disulfide is also used.[8] These options should be used daily but may also be used in conjunction with a ketoconazole shampoo regimen on alternate days.[8] It is unclear if other antifungals are equally effective, as this has not been sufficiently studied.[10] Antifungals that have been studied and found to be effective in the treatment of seborrhoeic dermatitis include ketoconazole, fluconazole, miconazole, bifonazole, sertaconazole, clotrimazole, flutrimazole, ciclopirox, terbinafine, butenafine, selenium disulfide, and lithium salts such as lithium gluconate and lithium succinate.[10][3]

Topical climbazole appears to have little effectiveness in the treatment of seborrhoeic dermatitis.[10] Systemic therapy with oral antifungals including itraconazole, fluconazole, ketoconazole is effective, but adverse side effects have been documented for fluconazole and ketoconazole, with the latter not recommended for use, while itraconazole, with its good safety profile, is the most commonly prescribed.[3] Terbinafine is said to be effective, but with adverse side effects, while other sources state it is not effective and should not be used.[3][11]

Anti-inflammatory treatments

[edit]

Topical corticosteroids are effective in short-term treatment of seborrhoeic dermatitis and are as effective or more effective than antifungal treatment with azoles. These are sometimes used for only a few weeks at a time.[11][additional citation(s) needed] There is also evidence for the effectiveness of topical calcineurin inhibitors like tacrolimus and pimecrolimus as well as lithium salt therapy.[26] Calcineurin inhibitors were also effective in reducing the growth of Malassezia, offering two routes by which they may treat seborrhoeic dermatitis.[25] Medications such as calcineurin inhibitors should not be used in individuals with seborrhoeic dermatitis who are immune-compromised because they cause further immune suppression.[11]

Oral immunosuppressive treatment, such as with prednisone, has been used in short courses for seborrhoeic dermatitis, as a last resort due to its potential side effects.[27]

Antihistamines

[edit]

Antihistamines are used primarily to reduce itching, if present. However, research studies suggest that some antihistamines have anti-inflammatory properties.[28]

Keratolytics

[edit]

Keratolytics help the skin via exfoliation of built-up skin flakes and thereby remove scale. They are applied topically to the affected area. Keratolytics include urea, salicylic acid, coal tar, lactic acid, pyrithione zinc and propylene glycol.[25] Coal tar shampoo formulations can be effective.[8][25] Although no significant increased risk of cancer in human treatment with coal tar shampoos have been found, caution is advised since coal tar is carcinogenic in animals, and heavy human occupational exposures do increase cancer risks.[29]

Other treatments

[edit]
  • Isotretinoin, a sebosuppressive agent, may be used to reduce sebaceous gland activity as a last resort in refractory disease.[30] However, isotretinoin has potentially serious side effects, and few patients with seborrhoeic dermatitis are appropriate candidates for therapy.[27]
  • Topical 0.75% and 1% Metronidazole[10][11]
  • Topical 4% nicotinamide[3]
  • Topical sulfacetamide[11]
  • Tea tree oil[12]
  • Cannabidiol shampoo[25]
  • Frequent washing to avoid the build-up of scale, especially on the scalp, but while avoiding overly drying the skin[12][11][21]
  • Avoiding damaging skin with harsh grooming or chemical irritants[21]
  • Bicalutamide, an antiandrogen, has been observed in one patient to have potentially been the cause of seborrheic dermatitis relief. However, even if it were demonstrated that bicalutamide or any other antiandrogen is a treatment, it is not recommended due to side effects and price.[31]

Phototherapy

[edit]
See also: Photodynamic therapy

Another option is natural and artificial UV radiation since it can inhibit the growth of Malassezia yeast.[32] Some recommend photodynamic therapy using UV-A and UV-B laser or red and blue LED light to inhibit the growth of Malassezia fungus and reduce seborrhoeic inflammation.[32][33][34]

Outcome

[edit]

Seborrhoeic dermatitis is generally a chronic and recurring condition. Individuals may have the condition for several weeks to months, but it may also last years or their lifetime. There may be periods of relapse and worsening.[11][8]

Epidemiology

[edit]

Seborrhoeic dermatitis affects 1 to 5% of the general population.[14][35][36] It is slightly more common in men, but affected women tend to have more severe symptoms.[36] The condition usually recurs throughout a person's lifetime.[37] Seborrhoeic dermatitis can occur in any age group[37] but often occurs during the first three months of life then again at puberty and peaks in incidence at around 40 years of age.[38][21] It can reportedly affect as many as 31% of older people.[36] Infants may also have this condition, though it is typically milder, and is referred to as cradle cap.[12] Seborrhoeic dermatitis is more common in African-Americans.[12]

Severity is worse in dry climates[37] as well as hot weather, as dry skin can exacerbate the condition.[12] COVID-19 related mask usage may also cause or exacerbate facial seborrhoeic dermatitis.[12]

Individuals who are immunocompromised have an increased risk of seborrhoeic dermatitis.[12] Conditions that are associated with increased rates of seborrhoeic dermatitis include individuals with HIV, Hepatitis C, alcoholic pancreatitis, Parkinson's disease, and alcohol abuse.[12] Seborrhoeic dermatitis is common in people with alcoholism, between 7 and 11 percent, which is twice the normal expected occurrence.[39]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Seborrhoeic dermatitis

View on Grokipedia
from Grokipedia
Seborrheic dermatitis is a common, chronic inflammatory that primarily affects sebaceous gland-rich areas such as the , face, and upper trunk, manifesting as papulosquamous lesions including scaly, erythematous patches with greasy yellow-white scales and, in some cases, small raised papules or bumps on the face, including the forehead and areas around the nose, often resembling in milder forms. It is noncontagious and tends to flare periodically, influenced by factors like stress, changes, and immune status, without causing permanent or scarring. Seborrheic dermatitis has two main forms: an infantile form (commonly known as cradle cap) that typically begins in the first few months of life and resolves spontaneously by 6-12 months of age, rarely persisting; and an adult form that often begins in late adolescence or early adulthood and is characterized by a chronic, relapsing course. The condition exhibits a bimodal age distribution, peaking in infancy and from late adolescence onward, with a global of approximately 4%–5% (pooled estimate 4.38% as of 2024) in the general population and up to 50% for alone.

Symptoms

Symptoms typically include persistent flaking and scaling of the skin, with oily or greasy patches that may appear or on lighter tones and purple, , or darker on brown or . Common sites include the (leading to ), eyebrows, area, ears, creases, and chest, often accompanied by mild to intense itching or soreness. In infants, it presents as thick, crusty scales on the known as , which usually resolves without treatment by age one. Severe cases may involve widespread involvement or secondary infections due to scratching.

Causes and Risk Factors

The exact etiology remains unclear but involves an interplay of yeast overgrowth on the skin, sebum production, and an abnormal , rather than direct or . , epidermal barrier dysfunction, and microbial contribute to its , with no single cause identified. Risk factors include neurological conditions like , immune suppression such as in (where prevalence can reach 35-85%), recovery from stressful illnesses like heart attacks, and certain demographics including men, individuals over 50, and those with oily skin or other dermatoses like . Environmental triggers such as cold, dry weather or fatigue can exacerbate flares.

Diagnosis and Management

Diagnosis is primarily clinical, based on the characteristic distribution and appearance of lesions, though may be used to rule out similar conditions like or eczema. There is no cure, but focuses on symptom control through topical antifungals (e.g., shampoo), mild corticosteroids, or inhibitors to reduce and proliferation. For severe or cases, oral antifungals or phototherapy may be considered, with regular maintenance therapy preventing recurrences. Early intervention by a dermatologist can significantly improve , as the condition is benign but can be persistent and cosmetically distressing.

Signs and symptoms

Presentation in adults

Seborrheic dermatitis in adults typically presents as red, inflamed skin with greasy, yellowish scales or plaques that primarily affect seborrheic areas rich in sebaceous glands. Common sites include the scalp, where it manifests as dandruff-like flaking; the face, particularly the nasolabial folds, eyebrows, eyelids, sides of the nose, forehead, and central face; the beard and mustache areas in men; the ears and postauricular regions; and the upper trunk, such as the chest and back. In more extensive cases, involvement may extend to the armpits, groin, or under the breasts. The skin lesions appear as erythematous to salmon-colored papules and plaques covered with fine, powdery scales or greasy yellowish crusts that adhere to oily skin, often described as yellowish or white in lighter skin tones, while in individuals with darker skin, they may present as pinkish, purplish, hypopigmented, or darker areas with less noticeable redness. Particularly on the face, including the forehead and areas around the nose, small raised papules or bumps may occur, which can appear small, red, salmon-colored, yellow-crusted, or darker depending on skin tone and inflammation level, reflecting the condition's papulosquamous morphology. Patients commonly experience mild to moderate itching or a burning sensation, which can be more intense on the scalp and may lead to scratching that exacerbates flaking. In severe scalp involvement, temporary hair shedding can occur due to inflammation-induced telogen effluvium, though it is reversible with treatment. Severity varies widely, from mild forms limited to flaky scalp scaling (often indistinguishable from dandruff) to moderate presentations with thin plaques and pruritus, or severe cases featuring extensive erythematous plaques, oozing or crusting in skin folds like the ears, and significant discomfort that disrupts daily activities. Dandruff represents the mildest variant, confined to the scalp without facial or body involvement, whereas full seborrheic dermatitis extends beyond this with more inflammatory features. The condition may be more prevalent or severe in adults with underlying disorders such as Parkinson's disease or HIV infection. The recurrent flaky scalp in seborrheic dermatitis, often perceived as "dry scalp" or dandruff, results from overgrowth of Malassezia yeast, excess sebum production, and an immune response leading to inflammation and accelerated epidermal turnover with flaking. The condition characteristically comes and goes, with flares triggered by stress, cold or dry weather, hormonal changes, illness, fatigue, or seasonal factors. This distinguishes it from pure dry scalp (xerosis) due to low humidity or harsh hair products, which may recur seasonally but is less likely to be chronically recurrent without persistent triggers.

Presentation in infants and children

Seborrhoeic dermatitis in infants, commonly known as cradle cap, typically manifests as thick, yellowish, greasy scales or crusts on the scalp, particularly affecting the vertex and frontal regions. These scales are often adherent and may form a firm, bran-like covering that binds the hair, but the condition is generally asymptomatic, with no associated itching or pain in most cases. The lesions can extend beyond the scalp to involve the forehead, eyebrows, postauricular areas, ears, and occasionally the neck or face in a T-shaped distribution along the nasolabial folds. Onset usually occurs between the second and third week of life, peaking in prevalence around 3 months of age, and the condition is self-limiting, resolving spontaneously in the majority of infants by 8 to 12 months without scarring or complications. In rare instances, infantile seborrhoeic dermatitis may present with involvement of intertriginous areas, such as the diaper region, axillae, or navel, where erythematous plaques with finer scaling predominate over thick crusts, sometimes leading to confusion with irritant diaper dermatitis. The disseminated form can affect the trunk or extremities minimally, but scalp involvement remains the hallmark. Four clinical subtypes have been described in infants: cephalic (limited to scalp), facial, diaper-type (genital and perineal), and disseminated, though the cephalic variant, or cradle cap, is by far the most common. Despite its greasy appearance, the scales are non-inflammatory and do not typically cause discomfort to the infant, though they may provoke parental concern due to cosmetic issues. In older children beyond infancy, seborrhoeic dermatitis tends to be milder and less prevalent, affecting approximately 7% in the second year of life and becoming rare after age 4. Presentation often mirrors a subtler version of the adult form, featuring fine, powdery scaling or flaking on the scalp, eyebrows, or behind the ears, with occasional mild erythema or subtle itching that rarely disrupts daily activities. Facial involvement may include the nasolabial folds or glabella, but widespread or severe scaling is uncommon, and the condition remains self-resolving in most pediatric cases without progression to chronicity. Persistent symptoms beyond 12 months warrant evaluation to exclude alternative diagnoses, as true seborrhoeic dermatitis in this age group is typically transient and tied to the maturation of sebaceous glands.

Diagnosis

Clinical diagnosis

The diagnosis of seborrhoeic dermatitis is primarily clinical, relying on a thorough visual examination of the skin and a detailed patient history, without the need for laboratory tests in typical cases. Clinicians identify characteristic lesions as erythematous patches or plaques covered with greasy, yellowish scales, often presenting in areas rich in sebaceous glands such as the , face (including nasolabial folds and eyebrows), ears, and upper trunk. These findings are corroborated by a history of chronic, relapsing symptoms that align with common presentations like flaky or facial scaling, typically occurring in otherwise healthy individuals without systemic involvement. Specific laboratory investigations, such as skin scrapings for fungal culture or , are rarely required and are reserved for atypical presentations where other conditions must be excluded. If a fungal etiology is suspected due to unusual features, adjunctive tools like dermoscopy may be employed to assess for dotted vessels or fine scaling patterns that support the diagnosis, while a Wood's lamp can help rule out fluorescence indicative of other dermatoses. Key diagnostic criteria include the symmetrical distribution of lesions in sebaceous gland-dense regions and the absence of systemic symptoms, such as fever or , which further affirm the clinical impression. This approach ensures accurate identification based on the disease's hallmark localization and morphology.

Differential diagnosis

Seborrhoeic dermatitis must be differentiated from other conditions that can present with recurrent flaky scalp, scaling, erythema, or pruritus in seborrhoeic areas such as the , face, and upper trunk. Distinguishing features include the distribution in oil-rich areas, greasy yellow scales, and mild pruritus, contrasting with more inflammatory or infectious mimics. Psoriasis typically features sharply demarcated erythematous plaques with thick, silvery-white scales, often involving the nails with pitting and lacking the greasy quality of seborrhoeic scales; it commonly affects extensor surfaces beyond seborrhoeic regions and can cause recurrent flaky scalp. In contrast to seborrhoeic dermatitis, psoriatic lesions show a positive Auspitz sign upon scale removal. Atopic dermatitis presents with more intense pruritus, dry and lichenified patches rather than oily scales, and a predilection for flexural areas like the antecubital and popliteal fossae, often with a personal or family history of . Unlike seborrhoeic dermatitis, it may involve weeping or crusting and spares the typical seborrhoeic distribution in many cases. Tinea capitis, a , is characterized by patchy alopecia, scaling with broken "black dot" hairs, and a scaly, elevated leading edge; diagnosis is confirmed by positive potassium hydroxide (KOH) preparation or fungal showing dermatophytes. It differs from seborrhoeic dermatitis by its association with and lack of diffuse greasy scaling, being more common in children than adults. Contact dermatitis often has an acute onset linked to exposure to irritants or allergens, such as shampoos or hair dyes, resulting in localized vesicular or eczematous reactions that resolve upon avoidance; it typically follows the of contact rather than seborrhoeic areas and can cause recurrent flaky scalp if exposure is repeated. Eyelid involvement or sharp demarcation from exposure sites further distinguishes it from the more chronic, symmetric distribution of seborrhoeic dermatitis. Simple dry scalp (xerosis) is characterized by fine, dry, white flakes on the scalp, often due to low humidity, harsh hair products, or excessive washing. It is non-inflammatory, lacking the erythema, greasy scales, and significant pruritus of seborrheic dermatitis. The flaking can recur seasonally with dry weather or due to triggers like harsh products, but is less likely to be chronically recurrent without persistent triggers. It differs from seborrheic dermatitis by the absence of inflammation and greasy quality, and usually improves with moisturizing and gentle hair care. Rosacea manifests as central facial , telangiectasias, and papules or pustules without significant scaling or scalp involvement, often accompanied by flushing or ocular symptoms like meibomianitis. , similarly, features comedones, inflammatory papules, and pustules primarily on the face, chest, or back, lacking the diffuse greasy crusts and seborrhoeic distribution seen in seborrhoeic dermatitis.

Etiology

Microbial causes

Seborrhoeic dermatitis is closely linked to the genus , a group of lipophilic yeasts that form part of the normal cutaneous and preferentially colonize sebaceous gland-rich areas such as the , face, and upper trunk. Among the 18 identified species, M. globosa and M. restricta are the most frequently implicated in the condition, comprising the majority of isolates from lesional . These yeasts thrive in lipid-rich environments, with overgrowth often triggered by increased sebum production during or other physiological changes that alter sebum composition, such as elevated levels of triglycerides and alongside reduced and free fatty acids. species produce lipases that metabolize sebum lipids into irritant free fatty acids, such as , which can disrupt the barrier and contribute to the initiation of dermatitis. Studies have demonstrated higher densities of in lesional compared to non-lesional or healthy skin, with quantitative cultures showing significantly elevated counts in affected areas of patients with seborrhoeic dermatitis. This overgrowth is supported by the clinical response to topical antifungals, such as , which reduce populations and lead to rapid symptom improvement, thereby establishing a causal association. Despite this role, seborrhoeic dermatitis is not contagious, as represents normal present from early infancy in both healthy individuals and those susceptible to the condition. Bacterial components of the skin microbiome also play a contributory role, with characterized by shifts in populations of (now classified as ) and species. is isolated more frequently from lesional skin of patients (49%) than from healthy controls (20%), potentially exacerbating the condition through secondary and promotion of . Coagulase-negative staphylococci, such as S. epidermidis, are predominant in seborrhoeic dermatitis lesions and decrease with effective treatment, suggesting involvement in microbial imbalance. appears underrepresented in affected skin and may indirectly support by hydrolyzing sebum to provide substrates for growth, though its density is often reduced compared to controls. Evidence of biofilm formation by these bacteria remains limited, but their altered abundance supports a model of secondary microbial contributions to disease initiation in susceptible individuals.

Individual susceptibility factors

Seborrheic dermatitis is associated with immune dysfunction, particularly impaired T-cell responses and altered complement activation, which may contribute to an inadequate reaction against skin commensals. Recent genomic studies (as of 2025) have identified a unique immune profile in SD, characterized by elevated Th17 and Th22 cytokines and mutations in barrier function genes, further supporting immune dysregulation as a key susceptibility factor. In individuals with , the prevalence ranges from 20% to 83%, linked to immune dysregulation that disrupts the skin's microbial balance. Similarly, patients with exhibit a strong association, potentially due to influences on peripheral immune function, including reduced T-cell activity. Organ transplant recipients on immunosuppressive therapy also show increased susceptibility, with studies reporting higher incidence rates attributed to diminished cellular immunity. Genetic predisposition to seborrheic dermatitis involves familial clustering and mutations in immune-related genes, though no single gene has been definitively established as causative. Hereditary deficiencies in the complement component C5, such as nonsense mutations in exons 1 and 36, have been identified in affected families, leading to SD-like phenotypes through impaired innate immunity. Polymorphisms in genes involved in inflammatory pathways, including those regulating IL-1 and TNF signaling, may heighten susceptibility by altering cytokine responses in the skin. Animal models, such as mice with seb gene mutations, further support a genetic basis, demonstrating inherited traits like sebaceous gland hyperactivity and epidermal changes. Nutritional deficiencies have been linked to seborrheic dermatitis in some cases, with evidence suggesting roles for , , and essential fatty acids, although causal relationships remain mixed. can manifest as periorificial resembling seborrheic dermatitis, due to impaired epidermal barrier function and immune modulation. deficiency commonly presents with seborrheic-like eruptions on the , face, and trunk, often in the context of or dietary inadequacy. Deficiencies in essential fatty acids may exacerbate symptoms through disrupted skin lipid composition, leading to increased and , though supplementation trials show variable efficacy. Hormonal influences, particularly , contribute to susceptibility by stimulating activity and sebum production, which is prominent during . Elevated levels, such as , enhance lipid secretion on the skin surface, creating an environment conducive to flares. Stress-induced hormonal shifts, including and surges, can similarly trigger exacerbations by altering sebum composition and immune responses in sebaceous areas.

Environmental factors

Seborrheic dermatitis tends to exacerbate in , dry climates, where low s and reduced impair the skin barrier and increase symptom . Studies in temperate regions demonstrate an inverse correlation between ambient and prevalence, with flares peaking during winter months when conditions are harshest on the skin. Conversely, symptoms often improve in warm, humid environments, particularly with higher exposure during summer, which may suppress inflammatory responses. Seasonal variations are pronounced in temperate zones, with the highest incidence reported in autumn and winter—up to 35% of cases—compared to only 13-14% in summer. Changes in season, such as the transition to drier air, commonly trigger outbreaks by altering hydration and microbial balance. These patterns highlight how environmental and UV index inversely influence disease activity, with low levels of both correlating to increased risk. Psychological stress frequently precedes flares of seborrheic dermatitis, with patients often identifying it as a primary trigger in a study of 82 individuals, where it was linked to poorer prognosis. Elevated cortisol from stress can stimulate sebum production, creating conditions favorable for symptom worsening, and is linked to higher recurrence rates and poorer prognosis. Lifestyle factors, including poor hygiene or use of occlusive hair products and detergents, may further aggravate the condition by trapping moisture and irritants on affected skin. Occupational exposures rarely cause seborrheic dermatitis but can exacerbate it through irritants or prolonged occlusion from in hot environments. For instance, workers in or similar industries wearing flame-retardant gear for extended periods may experience relapsing facial and scalp eruptions mimicking or worsening the disease. Such cases are often underreported and may be misdiagnosed as due to overlapping presentations.

Pathophysiology

Initiating factors

Seborrheic dermatitis often initiates through the interaction between excess sebum production and yeast proliferation on the skin surface. species, lipophilic fungi resident in sebaceous areas, metabolize sebum triglycerides via activity, releasing irritant free fatty acids such as and . These metabolites penetrate the , altering epidermal lipid composition and initiating early pathological changes. The microbial byproducts from this sebum-Malassezia interaction contribute to initial barrier disruption by inducing aberrant differentiation and abnormalities, such as parakeratosis and accumulation. This weakens the skin's protective barrier, allowing further penetration of irritants and setting the stage for disease onset without invoking a primary infectious process. , in particular, has been shown to disrupt the of epidermal , exacerbating susceptibility in seborrheic regions. Onset of seborrheic dermatitis frequently occurs post-puberty, coinciding with hormonally driven increases in sebaceous gland activity and sebum output, which provide an enriched substrate for growth. Trigger events such as , acute illness, or immune compromise can precipitate initial flares, often in an idiopathic manner without a clear precipitant. For instance, stress elevates levels that may indirectly promote sebum alterations, while conditions like infection heighten risk through subtle immune shifts. The disease follows a multifactorial model of , where no single factor predominates; instead, convergence of heightened sebaceous secretions, microbial colonization by , and host susceptibility—such as genetic predispositions affecting sebum composition—collectively drive the early events. This interplay underscores the idiopathic nature of many cases, with environmental modulators like seasonal changes amplifying the process.

Inflammatory and epidermal response

In seborrheic dermatitis, immune activation is primarily driven by antigens from Malassezia species, which stimulate T helper 1 (Th1) and Th17 cells, leading to the release of proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α). These cytokines promote local inflammation and activate the complement system, exacerbating the immune response in sebaceous gland-rich areas. Th17 cells further contribute by producing IL-17 and IL-22, which amplify keratinocyte responses and sustain chronic inflammation. This immune cascade induces epidermal hyperproliferation, characterized by abnormal keratinization that results in parakeratosis and the formation of adherent scales. In acute phases, spongiosis—intercellular within the —predominates, contributing to the erythematous and pruritic lesions. Chronic lesions exhibit psoriasiform , with thickened and reduced spongiosis, reflecting ongoing dysregulated epidermal turnover. Vascular changes accompany these processes, with cytokine-mediated dilation of superficial dermal vessels causing the hallmark observed in affected sites. The inflammatory and epidermal responses typically resolve with diminution of precipitating factors, such as reduced microbial burden or environmental stressors, allowing normalization of immune and barrier functions. However, relapses are frequent due to underlying individual susceptibility, including genetic predispositions to aberrant immune signaling and barrier defects.

Management

Seborrhoeic dermatitis in adults is highly manageable with consistent treatment, which can achieve dramatic and lasting improvement, with many patients experiencing near-total clearance of symptoms. Although no treatment eradicates the condition permanently, therapies including topical antifungals (e.g., ketoconazole, selenium sulfide) and newer options such as roflumilast foam render it controllable for most individuals, allowing symptom-free periods much of the time with suitable maintenance routines. Persistent flares may necessitate dermatologist consultation for personalized plans or assessment of related conditions.

Antifungal treatments

Antifungal treatments for seborrhoeic dermatitis primarily target the overgrowth of yeast species, which play a key role in the condition's . These agents, particularly azoles, are considered first-line for mild to moderate cases, reducing fungal load and alleviating symptoms such as , scaling, and pruritus. There is no single "best" shampoo for seborrheic dermatitis universally agreed upon in 2025, as effectiveness varies by individual. However, medicated shampoos with ketoconazole (e.g., Nizoral) are widely recommended as highly effective against the Malassezia yeast causing the condition. Other strong options include those with selenium sulfide, zinc pyrithione, or salicylic acid. In 2025 reviews, Nizoral, CeraVe Anti-Dandruff Hydrating Shampoo, and Jupiter Balancing Shampoo were highlighted for dandruff and seborrheic dermatitis relief. Topical azoles, such as 2% shampoo or cream, are commonly prescribed and applied 2-3 times weekly after initial daily use for 2-4 weeks, with the shampoo left on the scalp for 3-5 minutes before rinsing. In Sweden, ketoconazole 2% shampoo is available over-the-counter at pharmacies, with Fungoral 20 mg/ml being a widely recommended option. It treats both dandruff and seborrheic dermatitis by targeting the Malassezia fungus and is approved for adults and children over 12 years. The recommended usage is to apply it twice weekly for 2-4 weeks, leaving it on for 3-5 minutes before rinsing. If symptoms do not improve within one month or are severe, consult a physician for further assessment and possible complementary treatment, such as a corticosteroid solution. effectively decreases colonization and improves clinical symptoms, with studies showing significant reduction in scaling, itching, and flakes (approximately 70-80% improvement in trials). olamine serves as an effective alternative, available as 1% shampoo applied 2-3 times weekly or 0.77% twice daily, demonstrating superior tolerability and symptom relief in moderate to severe cases without notable differences between concentrations. Zinc pyrithione shampoos, with antifungal properties, are effective for mild to moderate cases, providing good long-term control of symptoms based on clinical evidence. Selenium sulfide shampoos (1-2.5%) offer another antifungal option, particularly for oily and scaly presentations, with studies indicating significant reduction in flaking and scaling. These antifungal shampoos are also applicable to facial and beard areas affected by seborrheic dermatitis, where the condition commonly manifests as beard dandruff with associated itch and flaking. Over-the-counter 1% ketoconazole shampoo (e.g., Nizoral A-D) can be applied to the damp beard and surrounding skin, lathered thoroughly, left on for several minutes (typically 3–5 minutes), and then rinsed off. For faster relief from flakes and itch, it is often used daily initially until symptoms improve, followed by maintenance use 2–3 times weekly or as directed. Similarly, anti-dandruff shampoos containing pyrithione zinc (e.g., Head & Shoulders) or selenium sulfide can be applied in the same manner for milder cases. Consultation with a physician is recommended if symptoms persist or do not improve. Overall, topical antifungals clear symptoms in approximately 70-90% of patients within 4 weeks, though maintenance therapy (e.g., twice-weekly applications) is recommended to prevent relapse. For severe or recalcitrant cases, oral antifungals like or may be used under medical supervision, with regular monitoring for hepatic effects due to potential systemic absorption. , typically dosed at 200-300 mg weekly for 2-4 weeks, has shown clinical efficacy in reducing symptoms, though results vary across studies. , administered as 200 mg daily for 1 week followed by intermittent dosing (e.g., 200 mg twice daily for 2 days monthly), achieves marked improvement in about 67-83% of patients by 3 months. Common side effects of topical antifungals include mild irritation, pruritus, or , which are generally well-tolerated with low incidence. Oral agents carry risks of , , , and rare , necessitating during treatment.

Anti-inflammatory treatments

treatments for seborrhoeic dermatitis primarily target the reduction of , pruritus, and scaling through suppression of inflammatory pathways in the skin. These agents are often used for short durations to manage acute flares, particularly in sensitive areas like the face and , where they provide symptomatic relief without addressing underlying microbial factors. Topical corticosteroids, such as 1% cream or 0.01% oil-based solution, are commonly prescribed for initial control of in seborrhoeic dermatitis. 1% is available over-the-counter and suitable for mild cases on the face and body, including beard areas affected by seborrhoeic dermatitis, where it provides quick relief from itch; it is applied sparingly to affected skin once or twice daily. Fluocinolone is particularly effective for involvement, where it can be applied as a shampoo or oil and left on for several minutes before rinsing. These agents are recommended for short-term use, typically 1-2 weeks, to minimize risks such as skin atrophy, , or , which can occur with prolonged application. Consult a doctor if symptoms persist. Calcineurin inhibitors, including 0.1% ointment and 1% cream, serve as steroid-sparing alternatives, especially for facial seborrhoeic dermatitis where long-term use is undesirable. and inhibit T-cell activation, reducing inflammation without the atrophogenic effects of corticosteroids. They are applied twice daily to affected areas and have shown in clearing symptoms within 2 weeks, with maintenance therapy possible for recurrent cases. These agents are particularly beneficial for periorificial regions, offering a safer profile for extended use in sensitive skin. Phosphodiesterase-4 (PDE4) inhibitors represent a newer non-steroidal class, with 0.3% foam (Zoryve) approved by the FDA in December 2023 for treating seborrhoeic dermatitis in patients aged 9 years and older. Applied once daily to the scalp and body, roflumilast foam targets cyclic AMP elevation to dampen release, providing broad coverage without the need for frequent dosing. Clinical trials demonstrated that 73.8% of patients achieved treatment success (Investigator Global Assessment score of 0 or 1 with at least a 2-grade improvement from baseline) after 8 weeks, compared to 40.9% with vehicle. Overall, treatments offer rapid symptom relief, with improvement rates ranging from 70-80% in responsive cases across classes, though long-term use requires monitoring for potential tolerance or side effects like in corticosteroids. Selection depends on location, severity, and patient factors, with non-steroidal options preferred for to avoid cutaneous thinning.

Adjunctive therapies

Adjunctive therapies for seborrhoeic dermatitis aim to alleviate symptoms such as scaling and itching through supportive measures that complement primary treatments. These include keratolytics to facilitate scale removal, antimicrobial agents like selenium sulfide for mild cases, and symptomatic relief options for pruritus. Keratolytics, such as shampoos containing 2% or 5% , are used to loosen and remove adherent scales from the and other affected areas, particularly in cases of thick, white, scaly, oily dandruff. These agents work by softening the hyperkeratotic , allowing easier , exfoliating the skin, and helping to control excess oil production; they are often combined with antifungal treatments for enhanced efficacy. Salicylic acid shampoos are typically applied 2-3 times weekly, left on for 5-10 minutes before rinsing. Clinical guidelines recommend their incorporation into maintenance regimens for moderate scaling, with evidence from randomized trials supporting their efficacy in reducing flaking without significant adverse effects. Selenium sulfide shampoos (0.5-2.5%) serve as an over-the-counter option for mild seborrhoeic dermatitis, particularly on the , by reducing overgrowth and scaling. Applied twice weekly, they provide and keratolytic benefits, though they are generally less effective than alternatives and may cause mild in sensitive . Systematic reviews indicate level C for their role in symptom control and relapse prevention in adult patients. For severe pruritus, oral antihistamines such as loratadine (10 mg daily) may be prescribed as an adjunct, especially when itching disrupts or is -mediated, as levels are elevated in affected individuals. These are rarely used as primary but offer symptomatic relief in refractory cases, with studies showing partial efficacy in dermatitic pruritus. Emollients, including fragrance-free creams or lotions like sorbolene, help hydrate dry, irritated skin and prevent barrier disruption in seborrhoeic dermatitis. Applied daily after cleansing, they reduce scaling and discomfort, particularly in or body involvement, and are supported by consensus for maintaining skin integrity. measures play a key role in , emphasizing gentle daily cleansing with mild, non-irritating shampoos and soaps to remove excess sebum and scales without exacerbating . During active flares of seborrhoeic dermatitis, particularly affecting the scalp, it is generally recommended to stop or minimize the use of many hair products to avoid further irritation. Patients should avoid styling products such as hair sprays, gels, pomades, and those containing alcohol, fragrances, or other irritants, as these can worsen symptoms. Instead, switch to gentle, fragrance-free, eczema-friendly shampoos or medicated antifungal shampoos (e.g., with ketoconazole or zinc pyrithione) as advised by a doctor, and avoid conditioners or other non-essential hair products during flares. Patients should also avoid other triggers like harsh detergents, alcohol-based products, and excessive heat, which can worsen symptoms. In cases of documented —associated with lower serum levels in seborrhoeic dermatitis patients—supplementation (e.g., 15-30 mg elemental daily) may improve outcomes, though routine use is not recommended without testing. Patients are advised to consult a dermatologist if there is no improvement after one month of treatment. This information is not personalized medical advice.

Phototherapy and other modalities

Phototherapy, particularly narrowband B (NB-UVB), serves as a non-pharmacological option for managing severe or refractory seborrhoeic dermatitis, typically administered 2-3 times per week in clinical settings. This modality targets widespread inflammatory lesions by delivering controlled doses of UVB light, starting at 50-70% of the minimal dose and incrementally increasing based on response, often over 8-12 weeks to achieve clearance. In a study of 10 patients with severe , NB-UVB treatment resulted in a clinical score reduction from 7.5 to 0.5 after 8 weeks, indicating near-complete resolution in most cases, with no serious adverse events reported during the course. The mechanism involves suppression of inflammatory responses in the skin, including induction of in activated T-cells, which contributes to decreased and scaling in affected areas. Efficacy is particularly notable in resistant patients, with response rates exceeding 70% in small cohorts when used for severe and involvement, though often occurs within months post-treatment. Combining NB-UVB with topical antifungals or keratolytics can enhance outcomes by addressing microbial and hyperkeratotic components simultaneously, leading to faster symptom control. Other procedural modalities include targeted laser therapies for localized plaques, though evidence is limited; (308 nm), which delivers focused UVB to small areas, has shown promise in analogous inflammatory conditions but requires further validation for seborrhoeic dermatitis. For hyperkeratotic variants, low-dose oral retinoids such as (e.g., 10-20 mg daily) offer an alternative in refractory cases, reducing sebum production and scaling with moderate efficacy and tolerability in clinical trials. One randomized trial demonstrated significant improvement in moderate-to-severe seborrhoeic dermatitis symptoms after 3 months of low-dose compared to , with sustained benefits in adherent patients. These approaches are reserved for cases unresponsive to first-line topicals due to risks including short-term or pruritus from phototherapy and potential long-term effects like premature skin aging or increased non-melanoma risk with cumulative UVB exposure. Oral retinoids carry risks of mucocutaneous dryness, , and teratogenicity, necessitating careful monitoring. Overall, phototherapy and retinoids are not first-line but provide valuable options for severe, treatment-resistant disease.

Maintenance therapy

Seborrhoeic dermatitis is a chronic condition requiring ongoing maintenance therapy to prevent relapses. No dedicated new international guidelines for maintenance therapy were issued specifically in 2024 or 2025. However, recent narrative reviews (2025) and updated resources (e.g., NICE CKS revised November 2024, AAFP 2025) emphasize its chronic nature and the need for maintenance to sustain remission. Maintenance typically involves reduced frequency of application after 2-4 weeks of initial daily or every-other-day treatment. Common recommendations include:
  • Topical antifungals (e.g., ketoconazole 2% shampoo or cream): once weekly or every 1-2 weeks after initial treatment.
  • Topical calcineurin inhibitors (e.g., tacrolimus 0.1% or pimecrolimus 1%): twice weekly for facial areas.
  • OTC shampoos (e.g., selenium disulfide, zinc pyrithione): once weekly or every other week.
  • Topical corticosteroids: limited twice-weekly use due to side effects.
Emerging option: roflumilast 0.3% foam (FDA-approved 2023, highlighted in 2025 reviews) for daily or as-needed long-term use.

Prognosis

Typical course and recurrence

Seborrheic dermatitis has two distinct forms with different typical courses: the infantile form, which is usually mild and self-limiting, resolving spontaneously by 6 to 12 months of age and rarely persisting into adulthood, and the adult form, which often begins in late adolescence or adulthood and follows a chronic relapsing course with periods of exacerbation and remission throughout life. The adult form typically follows a chronic relapsing course characterized by periods of exacerbation and remission, with symptoms often controllable through management but not curable. Flares may vary in intensity and duration due to natural fluctuations, commonly affecting sebaceous gland-rich areas like the scalp and face in a waxing and waning pattern over years. Recurrent flaky scalp, often perceived as dry scalp or dandruff, is a hallmark of seborrheic dermatitis. It results from overgrowth of Malassezia yeast, excess sebum production, and an immune-mediated inflammatory response that accelerates epidermal turnover and produces visible flaking. Symptoms tend to come and go, with flares commonly triggered by stress, cold and dry weather, hormonal changes, illness, fatigue, seasonal factors, or discontinuation of maintenance therapy, leading to renewed inflammation and scaling. Maintenance treatments, including weekly antifungal shampoos and emerging anti-inflammatory options due to rising antifungal resistance, help reduce relapse rates by addressing underlying contributors like Malassezia overgrowth and immune dysregulation. In infants, the condition—often manifesting as cradle cap—is generally mild and self-limiting, resolving spontaneously by 6 to 12 months of age without scarring or long-term sequelae. Persistence into adulthood is rare. For individuals with comorbidities such as HIV or Parkinson's disease, regular dermatologic follow-up is recommended to monitor disease progression and adjust management, as these conditions can exacerbate severity.

Complications and long-term effects

Seborrheic dermatitis can predispose affected individuals to secondary infections, particularly in moist intertriginous areas such as skin folds, the eyelids, or the nasolabial creases, where bacterial overgrowth like impetigo may occur due to scratching-induced skin barrier disruption. Fungal superinfections, including candidal overgrowth, are also possible in these regions, though they remain uncommon in otherwise healthy patients. Untreated scaling and inflammation may further exacerbate the risk of secondary bacterial invasion, leading to more severe local complications if not addressed promptly. The visible nature of seborrheic dermatitis often results in cosmetic concerns, including embarrassment from facial scaling or scalp flaking, which can contribute to social withdrawal and reduced self-esteem. Psychological impacts are significant, with patients frequently reporting heightened anxiety, depression, and feelings of stigma, particularly when symptoms affect appearance in social or professional settings. Seborrheic dermatitis does not directly cause permanent or excessive hair loss; however, in severe scalp involvement, temporary alopecia or shedding may arise indirectly from intense itching leading to scratching that injures hair follicles or from severe scalp inflammation. These effects typically do not result in permanent loss in most cases. These emotional burdens can persist even with controlled symptoms, underscoring the need for holistic management. Seborrheic dermatitis is associated with several comorbidities, notably worsening in patients with neurological conditions such as Parkinson's disease, where prevalence can reach 18-59% due to altered sebum production and immune responses. It may also intensify in immunocompromised states like HIV, but there is no established direct causation with malignancies such as skin cancer. These associations highlight the condition's interplay with underlying systemic factors rather than implying a causal role. Long-term effects of seborrheic dermatitis are generally mild, with minimal scarring in typical cases, though persistent inflammation on darker skin tones can lead to post-inflammatory hyperpigmentation or dyschromia. Recent research (as of 2025) emphasizes its immune-mediated nature with skin barrier dysfunction, enabling new targeted therapies that may improve long-term control and reduce complications. The condition often remains chronic and recurrent without addressing predisposing factors, such as immune dysregulation in HIV or neurological disorders, potentially prolonging symptoms over years. In rare severe instances, untreated scalp involvement may progress to scarring alopecia if follicular damage accumulates, but this is not the norm for most patients.

Epidemiology

Prevalence and incidence

Seborrheic dermatitis affects approximately 4.38% of the global , based on a of 121 studies involving over 1.26 million individuals with clinician-diagnosed cases. This pooled estimate (95% CI, 3.58%-5.17%) reflects moderate to severe presentations, with significant heterogeneity across studies (I² = 99.94%). When including milder forms such as , which represents a of the condition, rises substantially, affecting 10% to 50% of adults worldwide. In adults specifically, the is higher at 5.64% (95% CI, 4.01%-7.27%), while in children it stands at 3.70% (95% CI, 2.69%-4.80%). In infants, seborrheic dermatitis manifests primarily as , with prevalence ranging from 10% in the first month of life to a peak of up to 70% by three months, after which it typically resolves and declines to adult levels by . Annual incidence rates for new cases are estimated at around 1.7% to 1.9% globally and in high-income regions like the , derived from age-standardized incidence rates of 1,704 to 1,913 per 100,000 . In , the global burden included approximately 135.7 million incident cases, marking a 53% increase in absolute numbers since 1990, though age-standardized incidence rates have remained stable or slightly declined over decades. Geographic variations show higher prevalence in certain regions, such as 8.82% (95% CI, 3.00%-14.64%) in and 5.86% in , compared to 2.62% (95% CI, 1.33%-3.92%) in . Prevalence tends to be elevated in urban and industrialized areas, with no major shifts observed in recent meta-analyses up to 2023, including post-COVID-19 periods.

Demographic patterns and risk groups

Seborrheic dermatitis exhibits distinct age-related patterns, with incidence peaking in infancy (first of life), during , and in hood, particularly between 30 and 60 years of age. Among adults, the condition shows a bimodal distribution in males, with higher in young adults (20-40 years) and the elderly. In elderly populations, estimates are consistently higher than in the general , often exceeding 4% in those over 64 years. The condition is slightly more prevalent in males than females, with reported rates of approximately 6.6% in men compared to 5.4% in women in large population studies. This disparity is attributed to influences on sebum production, which promotes colonization and inflammation in sebaceous gland-rich areas. appears similar across ethnic groups, with no significant differences in incidence reported between populations. However, the condition often presents more severely in individuals of African descent due to darker tones that can mask , leading to underdiagnosis or delayed recognition of inflammatory changes. Certain comorbidities substantially elevate the risk of seborrheic dermatitis. In patients with or AIDS, prevalence ranges from 30% to 85%, increasing with disease progression and immune suppression. Similarly, up to 59% of individuals with develop the condition, potentially linked to neurological factors affecting sebaceous activity. is also heightened in alcoholics and those with depression, where prevalence is notably elevated compared to the general population, though exact rates vary by study.

History

Early descriptions

The recognition of seborrheic dermatitis as a distinct dermatological condition emerged in the late 19th century amid advancing histopathological studies. German dermatologist Paul Gerson Unna provided the first comprehensive description in 1887, introducing the term "seborrhoeal eczema" to denote an inflammatory disorder characterized by erythematous, scaly plaques in areas rich in sebaceous glands, such as the scalp, face, and upper trunk. Unna differentiated it from conventional eczema by emphasizing its greasy, adherent scales and tendency to affect seborrheic regions without the vesicular or weeping features typical of eczematous reactions. He further classified variants, including "seborrhoea sicca" for the drier, more scaly form, highlighting its chronic, relapsing nature. Early conceptualizations centered on dysregulated activity as the primary cause, with Unna positing that abnormal sebum secretion—either excessive or altered in quality—underlay the . This perspective lacked insight into microbial contributions, such as the role of yeasts or , which were not yet implicated. European clinicians, including those in and , documented similar presentations involving facial and scaling, often linking them to constitutional factors without etiological clarity. Debates persisted among contemporaries, with some rejecting the notion of a "dry" seborrhea as inconsistent with glandular hyperactivity.

Key developments in understanding and treatment

In the , the association between seborrheic dermatitis and yeasts, initially observed by Louis-Charles Malassez in 1874 through microscopic examination of skin scales, gained traction as a key etiological factor following advancements in . By the mid-, researchers linked the yeast (then termed Pityrosporum) to the condition's , with studies in the and demonstrating its overgrowth in affected areas. This understanding paved the way for the introduction of topical antifungals, such as in the , which targeted fungal proliferation and provided early symptomatic relief, marking a shift from symptomatic treatments like tars and keratolytics to etiology-focused therapies. The 1980s and 1990s brought further clarity on the immune-mediated aspects of seborrheic dermatitis, particularly through observations of its increased prevalence and severity in patients with HIV infection, highlighting the role of T-cell dysfunction in exacerbating the inflammatory response to Malassezia. This period also saw rigorous validation of antifungal efficacy, with randomized controlled trials (RCTs) establishing ketoconazole as a cornerstone treatment; for instance, a 1984 double-blind crossover study showed significant reductions in scaling and erythema compared to placebo. Into the 2000s, whole-genome sequencing of Malassezia species, notably M. globosa and M. restricta in 2007, revealed lipase genes responsible for sebum degradation and irritant production, solidifying the yeast's mechanistic contribution and informing targeted antifungal development. In the 2010s and early , genetic research advanced comprehension of susceptibility, with a 2018 pilot (GWAS) exploring candidate genes and loci, though no genome-wide significant associations were identified, underscoring the polygenic nature of the condition. Concurrently, high-throughput microbiome sequencing confirmed , showing elevated abundance alongside bacterial shifts in lesional skin, as detailed in 2022 analyses linking these alterations to barrier dysfunction and . A major therapeutic milestone occurred in 2023 with FDA approval of foam 0.3%, a phosphodiesterase-4 inhibitor, based on phase 3 RCTs demonstrating superior clearance rates over vehicle in moderate-to-severe cases, offering a non-antifungal, option. As of 2025, ongoing research explores modulation through , with clinical trials evaluating topical formulations for symptom relief and microbial balance, showing preliminary in reducing load. Additionally, early-phase investigations into biologic agents and JAK inhibitors, such as ruxolitinib cream, aim to target immune dysregulation more precisely, with phase 1/2 studies reporting tolerability and potential for refractory cases. These efforts reflect a continued toward personalized, mechanism-driven interventions.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK551707/
  2. https://www.merckmanuals.com/professional/dermatologic-disorders/dermatitis/seborrheic-dermatitis
  3. https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/symptoms-causes/syc-20352710
  4. https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-overview
  5. https://jamanetwork.com/journals/jamadermatology/fullarticle/2820685
  6. https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-symptoms
  7. https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-treatment
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4852869/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC7320655/
  10. https://www.ncbi.nlm.nih.gov/books/NBK531463/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11152465/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC9365318/
  13. https://www.aafp.org/pubs/afp/issues/2015/0201/p185.html
  14. https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/diagnosis-treatment/drc-20352714
  15. https://dermnetnz.org/topics/seborrhoeic-dermatitis
  16. https://emedicine.medscape.com/article/1108312-differential
  17. https://www.mayoclinic.org/diseases-conditions/dandruff/symptoms-causes/syc-20353850
  18. https://www.aad.org/public/everyday-care/hair-scalp-care/scalp/dry-scalp-conditions
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2923939/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC12256380/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC5955074/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/
  23. https://onlinelibrary.wiley.com/doi/10.1111/exd.14091
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6667642/
  25. https://www.researchgate.net/publication/321165912_The_Genetic_Basis_of_Seborrheic_Dermatitis_A_Review
  26. https://pubmed.ncbi.nlm.nih.gov/32125725/
  27. https://www.ccjm.org/content/83/10/731
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8721081/
  29. https://www.aafp.org/pubs/afp/issues/2006/0701/p125.pdf
  30. https://www.dynamed.com/condition/seborrheic-dermatitis-in-children-and-adults
  31. https://www.mysebdermteam.com/resources/hormones-and-seborrheic-dermatitis-whats-the-connection
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC9040311/
  33. https://www.va.gov/WHOLEHEALTHLIBRARY/tools/seborrheic-dermatitis.asp
  34. https://pubmed.ncbi.nlm.nih.gov/18033062/
  35. https://nationaleczema.org/types-of-eczema/seborrheic-dermatitis/
  36. https://www.liebertpub.com/doi/10.1097/DER.0000000000000923
  37. https://onlinelibrary.wiley.com/doi/10.1111/exd.14006
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC11942342/
  39. https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-025-03005-4
  40. https://karger.com/sad/article/9/3/160/835771/Scalp-Seborrheic-Dermatitis-What-We-Know-So-Far
  41. https://www.cosmopolitan.com/style-beauty/beauty/g69728871/best-dandruff-shampoo/
  42. https://www.glamour.com/gallery/best-dandruff-shampoos
  43. https://pubmed.ncbi.nlm.nih.gov/7718463/
  44. https://fass.se/product/19891013000020/pl
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC8465279/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC11976785/
  47. https://www.aad.org/public/everyday-care/skin-care-secrets/face/diy-treatment-common-beard-problems
  48. https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-self-care
  49. https://emedicine.medscape.com/article/1108312-treatment
  50. https://onlinelibrary.wiley.com/doi/10.1155/2014/705402
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221212/
  52. https://www.mayoclinic.org/drugs-supplements/fluconazole-oral-route/description/drg-20071428
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6483543/
  54. https://www.ncbi.nlm.nih.gov/books/NBK532940/
  55. https://pubmed.ncbi.nlm.nih.gov/19222250/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3579486/
  57. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217242s000lbl.pdf
  58. https://jamanetwork.com/journals/jamadermatology/fullarticle/2804569
  59. https://pubmed.ncbi.nlm.nih.gov/1835003/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3233984/
  61. https://pubmed.ncbi.nlm.nih.gov/15926215/
  62. https://dermnetnz.org/topics/seborrheic-dermatitis
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC7018314/
  64. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1093868/full
  65. https://pubmed.ncbi.nlm.nih.gov/11069503/
  66. https://pubmed.ncbi.nlm.nih.gov/15793518/
  67. https://pubmed.ncbi.nlm.nih.gov/28984153/
  68. https://pubmed.ncbi.nlm.nih.gov/39361685/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5683125/
  70. https://pubmed.ncbi.nlm.nih.gov/36789995/
  71. https://www.researchgate.net/publication/309432260_Low-dose_oral_isotretinoin_for_moderate_to_severe_seborrhea_and_seborrheic_dermatitis_A_randomized_comparative_trial
  72. https://pubmed.ncbi.nlm.nih.gov/27638433/
  73. https://pubmed.ncbi.nlm.nih.gov/35967915/
  74. https://cks.nice.org.uk/topics/seborrhoeic-dermatitis/
  75. https://www.aafp.org/pubs/afp/issues/2025/0800/seborrheic-dermatitis.html
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11909311/
  77. https://www.medscape.com/viewarticle/inflammation-now-key-target-seborrheic-dermatitis-2025a100005x
  78. https://my.clevelandclinic.org/health/diseases/14403-seborrheic-dermatitis
  79. https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults
  80. https://emedicine.medscape.com/article/1108312-clinical
  81. https://www.aafp.org/pubs/afp/issues/2000/0501/p2703.html
  82. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0331030
  83. https://www.healthline.com/health/seborrheic-dermatitis-hair-loss
  84. https://www.medicalnewstoday.com/articles/327257
  85. https://link.springer.com/article/10.1007/s13555-024-01288-9
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC9669556/
  87. https://karger.com/drm/article/237/6/872/828197/A-Review-of-the-Current-Evidence-Connecting
  88. https://www.arcutis.com/new-research-reveals-genomic-profile-of-seborrheic-dermatitis-and-answers-key-questions-on-immune-response-and-skin-barrier-dysfunction/
  89. https://nationaleczema.org/blog/seborrheic-dermatitis-what-the-latest-research-is-saying-from-how-it-develops-to-current-treatments-and-more/
  90. https://www.bosley.com/blog/seborrheic-dermatitis-hair-loss/
  91. https://emedicine.medscape.com/article/1108312-overview
  92. https://www.uptodate.com/contents/cradle-cap-and-seborrheic-dermatitis-in-infants
  93. https://www.expertmarketresearch.com/epidemiology-reports/seborrhea-epidemiology-forecast
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC12145784/
  95. https://pubmed.ncbi.nlm.nih.gov/15339072/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC8459174/
  97. https://pubmed.ncbi.nlm.nih.gov/28856679/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC9274933/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC12169496/
  100. https://accessmedicine.mhmedical.com/content.aspx?bookid=392&sectionid=41138717
  101. https://pubmed.ncbi.nlm.nih.gov/28705278/
  102. https://jamanetwork.com/journals/DERM/articlepdf/497816/archderm_10_4_005.pdf
  103. https://www.sciencedirect.com/science/article/pii/S1931312819301064
  104. https://archives.federalregister.gov/issue_slice/1982/12/3/54644-54704.pdf
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC9974923/
  106. https://pubmed.ncbi.nlm.nih.gov/6093845/
  107. https://pubmed.ncbi.nlm.nih.gov/18004291/
  108. https://www.researchgate.net/publication/321471415_The_Genetics_of_Seborrheic_Dermatitis_A_Candidate_Gene_Approach_and_Pilot_Genome-Wide_Association_Study
  109. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-3-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/
  110. https://www.clinicaltrials.gov/study/NCT07063615
  111. https://www.clinicaltrials.gov/study/NCT05787860
Add your contribution
Related Hubs
User Avatar
No comments yet.